Aminothiols and allantoin in chronic dialysis patients: Effects of hemodialysis sessions

Clinical Nephrology

Volumn 73, Issue 1, 2010, Pages 51-57

  Causse E ^a,c   Ribes, D ^a   Longlune, N ^a   Kamar, N ^a,c   Durand, D ^a,c   Salvayre, R ^a,c   Rostaing, L ^a,b,c  

^a CHU RANGUEIL   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Allantoin; Capillary electrophoresis; Chronic hemodialysis; Homocysteine; Oxidative stress; Purine compounds; Thiols

Indexed keywords

ALBUMIN; ALLANTOIN; AMINOTHIOL; C REACTIVE PROTEIN; CALCIUM; CREATININE; CYSTEINE; CYSTEINYLGLYCINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FERRITIN; FOLIC ACID; GLUTATHIONE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOXANTHINE; PARATHYROID HORMONE; PHOSPHORUS; POLYSULFONE; RECOMBINANT ERYTHROPOIETIN; URIC ACID;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CAPILLARY ELECTROPHORESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPARINIZATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; MALE; VASCULAR ACCESS; VITAMIN SUPPLEMENTATION;

EID: 74049108658     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP73051     Document Type: Article

References (30)

1. Andersson A, Lindgren A, Arnadottir M et al. Thiols as a measure of plasma redox status in healthy subjects and in patients with renal or liver failure. Clin Chem. 1999; 45:1 084-1086.
2. Apeland T, Kristensen O, Mansoor MA. The aminothiol redox status in haemodialysis patients does not improve with folate therapy. Scand J Clin Lab Invest. 2008; 29: 1-7.
3. Arnadottir M, Wingren K, Hultberg B, Hegbrant J. The postdialytic rise in the plasma total homocysteine concentration is delayed. Blood Purif. 2002; 20: 334-337.
4. Aslam S, Santha T, Leone A, Wilcox C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int. 2006; 70: 2109-2015.
5. Caussé E, Pradelles A, Dirat B et al. Simultaneous determination of allantoin, hypoxanthine, xanthine, and uric acid in serum/plasma by CE. Electrophoresis. 2007; 28: 381-387.
6. Caussé E, Siri N, Bellet H et al. Plasma homocysteine determined by capillary electrophoresis with laser-induced fluorescence detection. Clin Chem. 1999; 45: 412-414.
7. Covic A, Gusbeth-Tatomir P, Goldsmith DJ. The challenge of cardiovascular risk factors in endstage renal disease. J Nephrol. 2003; 16: 476-486.
8. Ducloux D, Klein A, Kazory A, Devillard N, Chalopin JM. Impact of malnutrition-inflammation on the association between homocysteine and mortality. Kidney Int. 2006; 69: 331-335.
9. Ducros V, Demuth K, Sauvant MP, Quillard M, Caussé E et al. Methods for homocysteine analysis and biological relevance of the results. J Chromatogr B. 2002; 781: 207-226.
10. Himmelfarb J, McMenamin E, McMonagle E. Plasma aminothiol oxidation in chronic hemodialysis patients. Kidney Int. 2002; 61: 705-716.
11. Kand'ar R, Zakova P, Muzakova V. Monitoring of antioxidant properties of uric acid in humans for a consideration measuring of levels of allantoin in plasma by liquid chromatography. Clin Chim Acta. 2006; 365: 249-256.
12. Kand'ar R, Zakova P. Allantoin as a marker of oxidative stress in human erythrocytes. Clin Chem Lab Med. 2008; 46: 1270-1274.
13. Kumagai H, Sakurai M, Takita T et al. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. Am J Kidney Dis. 2006; 48: 797-805.
14. Obeid R, Kuhlmann MK, Kohler H, Hermann W. Response of homocysteine, cystathionine, and methylmalonic acid to vitamin treatment in dialysis patients. Clin Chem. 2005; 51: 196-201.
15. Ozkan Y, Yardim-Akaydin S, Imren E, Torun M, Simsek B. Increased plasma homocysteine and allantoin levels in coronary artery disease: possible link between homocysteine and uric acid oxidation. Acta Cardiol. 2006; 61: 432-439.
16. Palleschi S, De Angelis S, Rossi B et al. Homocysteinemia correlates with plasma thiol redox status in patients with end-stage renal diseases. Nephron Clin Pract. 2008; 108: 106-112.
17. Panichi V, Rizza GM, Paoletti S et al. Chronic inflammation and mortality in hemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant. 2008; 23: 2337-2343.
18. Panichi V, Paoletti S, Consani C. Inflammatory pattern in hemodiafiltration. Contrib nephrol. 2008; 161: 185-190.
19. Parodi O, De Chiara B, Baldassarre D et al. Plasma cysteine and glutathione are independent markers of postmethionine load endothelial dysfunction. Clin Biochem. 2007; 40: 188-193.
20. Sasaki K, Motomiya Y, Oyama N, Hirao Y, Okajima E, Uji Y, Okabe H. Plasma allantoin in patients undergoing maintenance hemodialysis. Nippon Jinzo Gakkai Shi. 1996; 38: 164-170.
21. Scholze A, Rinder C, Beige J et al. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation. 2004; 109: 369-374.
22. Senol E, Ersoy A, Erdinc S, Sarandol E, Yurtkuran M. Oxidative stress and ferritin levels in haemodialysis patients. Nephrol Dial Transplant. 2008; 23: 665-672.
23. Sjoberg B, Anderstam B, Suliman M, Alvestrand A. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD. Am J Kidney Dis. 2006; 47: 60-71.
24. Stam F, van Guldener C, ter Wee PM, et al. Homocysteine clearance and methylation flux rates in health and end-stage renal disease: association with S-adenosylhomocysteine. Am J Physiol Renal Physiol. 2004; 287: 215-223.
25. Suliman M, Stenvinkel P, Qureshi AR, et al. The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol Dial Transplant. 2007; 22: 209-217.
26. Uzun H, Konukoglu D, Besler M, et al. The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein levels. Clin Invest Med. 2008; 31: 1-7.
27. van Guldener C. Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering? Nephrol Dial Transplant. 2006; 2: 1161-1166.
28. Vianna AC, Mocelin AJ, Matsua T, et al. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Kidney Int. 2007; 11: 210-216.
29. Wlodek PJ, Smolenski OB, Chwatko G, et al. Disruption of thiol homeostasis in plasma of terminal renal failure patients. Clin Chim Acta. 2006; 366: 137-145.
30. Zitnanova I, Korytar P, Aruoma O et al. Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms. Clin Chim Acta. 2004; 341: 139-146.